YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Bioh…
In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical da…
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron's cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already…
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international…
Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is ho…
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’ Continue Reading
Options button on browser by Pashalgnatov via iStock After yesterday's bounceback -- all three major U.S. indices were up nicely: S&P 500 +1.69%, Dow Jones Industrial Average +0.61%, and Nasdaq Composite +1.14% -- you might have expected a…
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’ Continue Reading
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. Continue Reading
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit. Continue Reading
Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Red stock chart with arrow going down ©Shutterstock Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1.9% to $15.40 in premarket trading after RBC Capital downgraded the company to Sector Perform from Outperform and lowered its price target…
On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven's lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up ex…
By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company's subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose…
Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive wo…
Medical research testing ©rawpixel Biohaven Ltd. (NYSE:BHVN) shares gained 7% on Wednesday after the biotechnology company announced a strategic global licensing agreement with SK Biopharmaceuticals covering its Kv7 ion channel platform an…
Paves the Way to Launch its Second Innovative Drug Directly in the U.S. Announces agreement to in-license near-commercial candidate at a press conference Targets U.S. commercial launch as early as 2029… Upfront and milestone payments relat…
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the…
Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron…
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented f…
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug development NEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ -- Biohaven Ltd. (NYS…
Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with…
Bexorg, Inc. -Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development -Combined leade…
Biohaven announced a series of scientific leadership changes, including the upcoming transition of Bruce Car, Ph.D., to Chief Innovation Officer, the promotion of David Pirman, Ph.D., to Executive Vice President and Head of Discovery, and…
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations Warren Volles, General…
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Performing American Stocks in June 2026. On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-con…
With EPS growth for the next five years forecasted at 31.63%, Biohaven Ltd. (NYSE:BHVN) is among the 12 Best Quality Stocks to Buy and Hold for the Next Decade. On June 29, BofA downgraded Biohaven Ltd. (NYSE:BHVN) to Underperform from Neu…
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinf…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.25%. September E-mini S&P futures (ESU26) rose +1.20%, and Sept…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.59%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.25%. September E-mini S&P futures (ESU26) rose +1.20%, and Sept…
The S&P 500 Index ($SPX) (SPY) is up +0.73% today; the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.08%. September E-mini S&P futures (ESU26) are up +0.76%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.59%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.67%. September E-mini S&P futures (ESU26) are up +0.73%, and September E-mini N…
Investing.com -- Bank of America downgraded four U.S. biopharmaceutical companies, lowering ratings on Alkermes, Amphastar Pharmaceuticals and Biohaven to Underperform, while cutting Liquidia to Neutral, citing a combination of stretched v…
The S&P 500 Index ($SPX) (SPY) is up +0.73% today; the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.08%. September E-mini S&P futures (ESU26) are up +0.76%, and September E-mini N…
The S&P 500 Index ($SPX) (SPY) today is up +0.59%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.67%. September E-mini S&P futures (ESU26) are up +0.73%, and September E-mini N…